Association of Barrett's Esophagus With Type II Diabetes Mellitus: Results From a Large Population-based Case-Control Study

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 9, 2013, Pages 1108-1114.e5

  Iyer, Prasad G ^a   Borah, Bijan J ^a   Heien, Herbert C ^a   Das, Ananya ^b   Cooper, Gregory S ^c   Chak, Amitabh ^c  

^a MAYO CLINIC   (United States)

^b Arizona Center for Digestive Health   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Epidemiology; Esophageal Adenocarcinoma; Insulin Resistance; Visceral Obesity

Indexed keywords

ADULT; ARTICLE; BARRETT ESOPHAGUS; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOSCOPY; ETHNICITY; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; RISK FACTOR; SEX DIFFERENCE; SMOKING;

BARRETT'S ESOPHAGUS; BE; BMI; BNF; BODY MASS INDEX; BRITISH NATIONAL FORMULARY; DM2; EAC; EPIDEMIOLOGY; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX DISEASE; GENERAL PRACTICE RESEARCH DATABASE; GERD; GPRD; IGF; INSULIN RESISTANCE; INSULIN-INSULIN GROWTH FACTOR; ODDS RATIO; OR; TYPE 2 DIABETES MELLITUS; VISCERAL OBESITY;

ADULT; AGED; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT;

EID: 84882263647     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.03.024     Document Type: Article

References (50)

1. Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med 2009, 361:2548-2556.
2. Whiteman D.C., Sadeghi S., Pandeya N., et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008, 57:173-180.
3. Chow W.H., Blot W.J., Vaughan T.L., et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998, 90:150-155.
4. Cook M.B., Greenwood D.C., Hardie L.J., et al. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol 2008, 103:292-300.
5. Kamat P., Wen S., Morris J., et al. Exploring the association between elevated body mass index and Barrett's esophagus: a systematic review and meta-analysis. Ann Thorac Surg 2009, 87:655-662.
6. Abrams J.A., Sharaiha R.Z., Gonsalves L., et al. Dating the rise of esophageal adenocarcinoma: analysis of Connecticut tumor registry data, 1940-2007. Cancer Epidemiol Biomarkers Prev 2011, 20:183-186.
7. Corley D.A., Kubo A., Levin T.R., et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007, 133:34-41. quiz 311.
8. Edelstein Z.R., Farrow D.C., Bronner M.P., et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007, 133:403-411.
9. Das A., Thomas S., Zablotska L.B., et al. Association of esophageal adenocarcinoma with other subsequent primary cancers. J Clin Gastroenterol 2006, 40:405-411.
10. Nelsen E.M., Kirihara Y., Takahashi N., et al. Distribution of body fat and its influence on esophageal inflammation and dysplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2012, 10:728-734.
11. El-Serag H.B., Graham D.Y., Satia J.A., et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005, 100:1243-1250.
12. Pandolfino J.E., El-Serag H.B., Zhang Q., et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 2006, 130:639-649.
13. Tilg H., Moschen A.R. Visceral adipose tissue attacks beyond the liver: esophagogastric junction as a new target. Gastroenterology 2010, 139:1823-1826.
14. Jinjuvadia R., Lohia P., Jinjuvadia C., et al. The association between metabolic syndrome and colorectal neoplasm: systemic review and meta-analysis. J Clin Gastroenterol 2013, 47:33-44.
15. Johansen D., Stocks T., Jonsson H., et al. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev 2010, 19:2307-2317.
16. Rosato V., Bosetti C., Talamini R., et al. [Metabolic syndrome and the risk of breast cancer]. Recenti Prog Med 2011, 102:476-478.
17. Pelucchi C., Serraino D., Negri E., et al. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 2011, 21:835-841.
18. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
19. Greer K.B., Thompson C.L., Brenner L., et al. Association of insulin and insulin-like growth factors with Barrett's oesophagus. Gut 2012, 61:665-672.
20. Rubenstein J.H., Davis J., Marrero J.A., et al. Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Aliment Pharmacol Ther 2005, 22:267-271.
21. Neale R.E., Doecke J.D., Pandeya N., et al. Does type 2 diabetes influence the risk of oesophageal adenocarcinoma?. Br J Cancer 2009, 100:795-798.
22. Jick H., Jick S.S., Derby L.E. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991, 302:766-768.
23. Yang Y.X., Hennessy S., Lewis J.D. Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol 2005, 3:587-594.
24. Prentice R.L., Kalbfleisch J.D., Peterson A.V., et al. The analysis of failure times in the presence of competing risks. Biometrics 1978, 34:541-554.
25. Jick S.S., Kaye J.A., Vasilakis-Scaramozza C., et al. Validity of the general practice research database. Pharmacotherapy 2003, 23:686-689.
26. Lawrenson R., Williams T., Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999, 21:299-304.
27. Solaymani-Dodaran M., Logan R.F., West J., et al. Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study. Am J Gastroenterol 2005, 100:2616-2621.
28. Solaymani-Dodaran M., Logan R.F., West J., et al. Risk of extra-oesophageal malignancies and colorectal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Scand J Gastroenterol 2004, 39:680-685.
29. Solaymani-Dodaran M., Logan R.F., West J., et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004, 53:1070-1074.
30. El-Serag H., Hill C., Jones R. Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK general practice research database. Aliment Pharmacol Ther 2009, 29:470-480.
31. Dupont W.D. Power calculations for matched case-control studies. Biometrics 1988, 44:1157-1168.
32. Ai C., Norton E.C. Interaction terms in logit and probit models. Econ Lett 2003, 80:123-129.
33. Buis M.L. Stata tip 87: interpretation of interactions in nonlinear models. Stata J 2010, 305-308.
34. El-Serag H.B., Kvapil P., Hacken-Bitar J., et al. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005, 100:2151-2156.
35. Nam S.Y., Kim B.C., Han K.S., et al. Abdominal visceral adipose tissue predicts risk of colorectal adenoma in both sexes. Clin Gastroenterol Hepatol 2010, 8:443-450. e441-442.
36. Ryan A.M., Healy L.A., Power D.G., et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg Jun 2008, 247:909-915.
37. Leggett C.L., Nelsen E., Tian J., et al. Metabolic syndrome as a risk factor for Barrett's esophagus: a population based case control study. Mayo Clin Proc 2013, 88:157-165.
38. Chen S.C., Chou C.K., Wong F.H., et al. Overexpression of epidermal growth factor and insulin-like growth factor-I receptors and autocrine stimulation in human esophageal carcinoma cells. Cancer Res 1991, 51:1898-1903.
39. Liu Y.C., Leu C.M., Wong F.H., et al. Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J Biomed Sci 2002, 9:665-674.
40. Takaoka M., Harada H., Andl C.D., et al. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res 2004, 64:7711-7723.
41. Kendall B.J., Macdonald G.A., Hayward N.K., et al. Leptin and the risk of Barrett's oesophagus. Gut 2008, 57:448-454.
42. Thompson O.M., Beresford S.A., Kirk E.A., et al. Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity (Silver Spring) 2010, 18:2204-2211.
43. Gao Q., Horvath T.L. Cross-talk between estrogen and leptin signaling in the hypothalamus. Am J Physiol Endocrinol Metab 2008, 294:E817-E826.
44. Kelty C.J., Gough M.D., Van Wyk Q., et al. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol 2007, 42:1271-1274.
45. Hahn H.P., Blount P.L., Ayub K., et al. Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. Am J Surg Pathol 2009, 33:1006-1015.
46. Liu W., Hahn H., Odze R.D., et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol 2009, 104:816-824.
47. Edelstein Z.R., Bronner M.P., Rosen S.N., et al. Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study. Am J Gastroenterol 2009, 104:834-842.
48. El-Serag H. Role of obesity in GORD-related disorders. Gut 2008, 57:281-284.
49. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4:579-591.
50. Omer Z.B., Ananthakrishnan A.N., Nattinger K.J., et al. Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol 2012, 10:722-727.